Smoothened Homolog (Protein Gx or SMO) Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Smoothened
Homolog (Protein Gx or SMO) – Pipeline Review, H1 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

According to the recently published report ‘Smoothened Homolog –
Pipeline Review, H1 2019’; Smoothened Homolog (Protein Gx or SMO)
pipeline Target constitutes close to 14 molecules. Out of which
approximately 11 molecules are developed by companies and remaining by
the universities/institutes.

Smoothened Homolog (Protein Gx or SMO) – Smoothened homolog (SMO) is a G
protein-coupled receptor that probably associates with the patched
protein (PTCH) to transduce the hedgehog’s proteins signal. Binding of
sonic hedgehog (SHH) to its receptor is thought to prevent normal
inhibition by patched of smoothened (SMO). It is required for the
accumulation of KIF7 and GLI3 in the cilia.

The report outlays comprehensive information on the Smoothened Homolog
(Protein Gx or SMO) targeted therapeutics, complete with analysis by
indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type; that are being developed by
Companies / Universities.

It also reviews key players involved in Smoothened Homolog (Protein Gx
or SMO) targeted therapeutics development with respective active and
dormant or discontinued projects. Currently, The molecules developed by
companies in Phase III, Phase II, Phase I, Preclinical and Discovery
stages are 2, 3, 2, 3 and 1 respectively. Similarly, the universities
portfolio in Preclinical and Discovery stages comprises 2 and 1
molecules, respectively.

Scope

• The report provides a snapshot of the global therapeutic landscape for
  Smoothened Homolog (Protein Gx or SMO)
• The report reviews Smoothened Homolog (Protein Gx or SMO) targeted
  therapeutics under development by companies and universities/research
  institutes based on information derived from company and
  industry-specific sources
• The report covers pipeline products based on various stages of
  development ranging from pre-registration till discovery and
  undisclosed stages
• The report features descriptive drug profiles for the pipeline
  products which includes, product description, descriptive MoA, R&D
  brief, licensing and collaboration details & other developmental
  activities
• The report reviews key players involved in Smoothened Homolog (Protein
  Gx or SMO) targeted therapeutics and enlists all their major and minor
  projects
• The report assesses Smoothened Homolog (Protein Gx or SMO) targeted
  therapeutics based on mechanism of action (MoA), route of
  administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline
  projects
• The report reviews latest news and deals related to Smoothened Homolog
  (Protein Gx or SMO) targeted therapeutics

Companies Mentioned

• AlfaSigma SpA
• F. Hoffmann-La Roche Ltd
• Genentech Inc
• Guangdong Zhongsheng Pharmaceutical Co Ltd
• IMPACT Therapeutics Inc
• Mayne Pharma Group Ltd
• PellePharm Inc
• Pfizer Inc
• Sun Pharma Advanced Research Company Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/8wsqnk

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs